Home › Compare › RPNMF vs ABBV
RPNMF yields 137.93% · ABBV yields 3.06%● Live data
📍 RPNMF pulled ahead of the other in Year 1
Combined, RPNMF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RPNMF + ABBV for your $10,000?
Rapala VMC Corporation, together with its subsidiaries, engages in manufacturing, sourcing, and distributing fishing tackle products in North America, Nordic countries, rest of Europe, and internationally. It operates through two segments, Group Products and Third Party Products. The company offers products used in lures for hard baits, and also for fishing accessories, clothing, luggage, and eyewear; metal lures specifically designed for salmon and trout fishing, and trolling in fresh and salt water; braided and monofilament lines, and specialized leader lines; hooks used for sport fishing and commercial hooks, and terminal tackles; hard baits, hybrids and rigged, and unrigged soft baits; specialized trolling lures and metal jigs for saltwater big game fishing; baits for carp, match, and coarse fishing; and knives for filleting, outdoor, hunting, and kitchen use, as well as ice augers and auger blades, and cross country skis. Its brand portfolio includes Rapala and other international brands, such as VMC, Sufix, Storm, Blue Fox, Luhr Jensen, Williamson, Dynamite Baits, Mora Ice, Trigger, Marttiini, and Peltonen. Rapala VMC Corporation was founded in 1936 and is based in Helsinki, Finland.
Full RPNMF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.